Lincoln Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹163Cr
- +1.2% YoY
- +5.8% QoQ
- Net profit
- ₹20Cr
- −23.1% YoY
- −28.6% QoQ
- Margin
- 16%
- −2 pp YoY
- +1 pp QoQ
Guidance rank: #55 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Lincoln Pharmaceuticals Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
EBITDA: ₹2,927 Crore, a YoY increase of 10.4% - Operating Margin: 27.4%, a YoY improvement of 110 basis points (bps) - Profit After Tax (PAT): ₹1,852 Crore, a YoY growth of 16.7% - Margin Outlook: The
From Lincoln Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Lincoln Pharmaceuticals Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 163 | 161 | +1.2% | 154 | +5.8% |
| Operating profit (EBITDA) | 25 | 28 | -10.7% | 24 | +4.2% |
| Operating margin | 16% | 18% | -2 pp | 15% | +1 pp |
| Profit before tax | 29 | 35 | -17.1% | 35 | -17.1% |
| Net profit (PAT) | 20 | 26 | -23.1% | 28 | -28.6% |
| EPS (₹) | 9.98 | 13.15 | -24.1% | 13.82 | -27.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q2 FY26 results?
EBITDA: ₹2,927 Crore, a YoY increase of 10.4% - Operating Margin: 27.4%, a YoY improvement of 110 basis points (bps) - Profit After Tax (PAT): ₹1,852 Crore, a YoY growth of 16.7% - Margin Outlook: The
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
